N@N

Market Maker Surveillance Report. TELK, VVTV, OSIR, OMER, LSCG, FMNL, Losing Stocks With Lowest Price Friction For Wednesday,

June 27, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3609 companies with "abnormal" market making, 3656 companies with positive Friction Factors and 2015 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. TELIK INC (NASDAQ:TELK), VALUEVISION MEDIA INC-A (NASDAQ:VVTV), Osiris Therapeutics Inc (NASDAQ:OSIR), OMEROS CORP (NASDAQ:OMER), LIGHTING SCIENCE GROUP CORP (OTC:LSCG), FORUM NATIONAL INVESTMENTS LTD N (OTC:FMNL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  TELK    $-0.280   -11.86%   72,340       44.13%    89,606       54.66%    -17,266      -617    
  VVTV    $-0.240   -10.34%   163,647      39.62%    249,414      60.38%    -85,767      -3,574  
  OSIR    $-2.480   -17.93%   690,721      48.06%    722,846      50.30%    -32,125      -130    
  OMER    $-2.670   -20.15%   1,225,433    46.44%    1,406,569    53.30%    -181,136     -678    
  LSCG    $-0.180   -11.11%   45,124       26.11%    83,252       48.17%    -38,128      -2,118  
  FMNL    $-0.470   -26.11%   30,577       18.53%    49,550       30.03%    -18,973      -404    

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows TELK with a dollar loss Wednesday of $-0.28000 and a Friction Factor of -617 shares. That means that it only took 617 more shares of selling than buying to move TELK lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

TELIK INC (NASDAQ:TELK) - Telik, Inc., a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer. The companys advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy; and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Its preclinical drug product candidates for the treatment of cancer comprise TLK60404, a small molecule compound inhibiting Aurora kinase and VEGFR kinase; and TLK60596, a small-molecule dual inhibitor of VEGFR1 and VEGFR2 kinase. Telik's product candidates are discovered using its proprietary drug discovery technology, TRAP that enables the rapid and efficient discovery of small molecule drug candidates. The company was founded in 1988 and is based in Palo Alto, California.

VALUEVISION MEDIA INC-A (NASDAQ:VVTV) - ValueVision Media, Inc., a multi-media retailer, engages in marketing, selling, and distributing its products directly to consumers through various digital platforms. It sells mens and womens watches, collectible coins, and other collectible items; gold, gemstone, and fashion jewelry for men and women; and consumer electronics, including desktop and notebook computers and related accessories, as well as home electronics, such as LCD televisions and digital cameras. The company also offers apparel, fashion accessories, and health and beauty products comprising clothing and footwear for women; handbags and other fashion accessories; and cosmetics and personal care items, as well as home and other products, consisting of mattresses, sheet sets, lamps, and home furnishings. Its principal form of multi-media retailing is its television shopping network, ShopNBC, which markets brand name and private label products. The companys other distribution channel includes its Internet retailing Web sites, such as ShopNBC.com and ShopNBC.TV, which provide a range of consumer merchandise, including various products being featured in its television programming. It also provides its products through other digital platforms comprising mobile and social media. ValueVision Media has strategic alliances with GE Capital Equity Investments, Inc. and NBC Universal, Inc. The company was founded in 1990 and is headquartered in Eden Prairie, Minnesota.

Osiris Therapeutics Inc (NASDAQ:OSIR) - Osiris Therapeutics, Inc., a stem cell therapeutic company, focuses on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States and internationally. Its lead biologic drug candidate includes Prochymal, which is in Phase 3 clinical trials for the treatment of acute and steroid refractory graft versus host disease (GvHD) and Crohn's disease, as well as for the repair of gastrointestinal injury resulting from radiation exposure. The company is also developing its Prochymal drug candidate for the repair of heart tissue following a heart attack, and for the protection of pancreatic islet cells in patients with type 1 diabetes. In addition, it is developing Chondrogen, a biologic drug candidate for the treatment of osteoarthritis and the reduction of pain in the knee. Additionally, the company focuses on developing biologic products for use in surgical procedures. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for developing Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for the distribution of Prochymal for GvHD in Japan. Osiris Therapeutics was founded in 1992 and is headquartered in Columbia, Maryland.

OMEROS CORP (NASDAQ:OMER) - Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products focused on inflammation and disorders of the central nervous system. Its product candidates are derived from its proprietary PharmacoSurgery platform that is designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The companys lead PharmacoSurgery product candidate, OMS103HP, is in Phase III clinical program for evaluating OMS103HPs safety and ability to improve postoperative joint function and reduce pain following arthroscopic anterior cruciate ligament; and to reduce pain and improve postoperative joint function following arthroscopic meniscectomy surgery. Its PharmacoSurgery product candidates also include OMS302, which completed its Phase I/II clinical trial for use during ophthalmological procedures; and OMS201, which is in Phase I/II clinical trial for use during urological surgery. The company also engages in developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPARγ) agonists for the treatment and prevention of addiction to substances of abuse. Its pipeline of preclinical product development programs include MASP-2 program for developing proprietary mannan-binding lectin-associated serine protease-2 antibody therapies to treat disorders caused by complement-activated inflammation; PDE10 program for developing proprietary compounds to treat schizophrenia and other psychotic disorders; PDE7 program for developing proprietary compounds to treat movement disorders; and GPCR program for the de-orphanization of orphan G protein-coupled receptors. Omeros Corporation was founded in 1994 and is based in Seattle, Washington.

LIGHTING SCIENCE GROUP CORP (OTC:LSCG) - Lighting Science Group Corporation engages in the research, design, development, manufacture, and marketing of various lighting devices and systems that use light emitting diodes (LED) as the light source primarily in the United States and the Netherlands. The companys product line consists of LED luminaires or fixtures, including PROLIFIC Series Roadway Luminaire used in street lighting applications; the Pyramid Low Bay, Flat Low Bay, and BAYLUME luminaires used in parking garages and other area lighting; and The ShoeBox and WallPack LED luminaires for area and pathway and security lighting, as well as a range of LED retrofit lamps or bulbs. It also provides the SYMETRIE line of LED luminaires; and a range of LED-based spot, accent, recessed, pendant, and track lighting products for retail display applications. In addition, the company offers architectural and architainment LED lighting devices, including the Color Tile, FLEXILUME, XTREMETUBE, High Power Linear, DOTZ, COOLGRID, and Flat RGB luminaires; and white light and RGB LED modules under the ATLAS and TITAN trademarks, as well as provides customized LED lighting systems or solutions. It primarily offers its products to public and private infrastructure, retail and hospitality, commercial and industrial, and architectural and architainment markets. The company sells its products through direct sales, as well as through alliances with channel partners, such as original equipment manufacturers, lighting designers, electrical and lighting distributors, and energy service companies. Lighting Science Group Corporation is headquartered in Satellite Beach, Florida.

FORUM NATIONAL INVESTMENTS LTD N (OTC:FMNL) -

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net